Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

696.03 +1.04 (+0.15%)
Streaming Delayed Price Updated: 2:56 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
57 58 Next >
News headline image
Top Biotech Roivant, Formed By Vivek Ramaswamy, Reports Steep Losses, Light Sales ↗
The company is working on a treatment for stomach diseases ulcerative colitis and Crohn's disease. 
Via Investor's Business Daily
News headline image
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet ↗
Investors are on the hunt for undervalued, underfollowed and emerging stocks, and retail traders have countless methods at their disposal to uncover new information. For some, this may be... 
Via Benzinga
News headline image
Why the quality investor may take a look at NASDAQ:REGN. ↗
REGENERON PHARMACEUTICALS (NASDAQ:REGN) may be suited for quality investing, we'll explore why in this article. 
Via Chartmill
News headline image
The 7 Best Value Stocks to Buy in August ↗
Stop chasing the hot flavors of the week and instead be friendly to your wallet with these ideas for best value stocks to buy. 
Via InvestorPlace
News headline image
Regeneron's Aflibercept 8mg Shows Sustained Vision Gains At Two Years ↗
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced two-year (96 weeks) topline data from the pivotal PULSAR trial investigating aflibercept 8 mg in patients with wet age-related  
Via Benzinga
News headline image
This Is What Whales Are Betting On Regeneron Pharmaceuticals ↗
 
Via Benzinga
News headline image
(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest ↗
 
Via Benzinga
News headline image
Regeneron Surmounts Its 200-Day Line On A Handy Second-Quarter Beat ↗
Shares have been trapped below their 200-day moving average since late June. 
Via Investor's Business Daily
News headline image
Two-year PULSAR Trial Results for Aflibercept 8 mg Demonstrate Durable Vision Gains at Extended Dosing Intervals in Wet Age-related Macular Degeneration
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
3 Top Biotech Stocks Defying the Bear Market ↗
Biotech is still booming, if you pick the right biotech stocks. 
Via The Motley Fool
News headline image
Health Care Company Regeneron Pharmaceuticals Announces Acquisition of Decibel Therapeutics ↗
 
Via Benzinga
News headline image
Decibel Therapeutics (DBTX) Stock Skyrockets 71% on Regeneron Deal ↗
Decibel Therapeutics (DBTX) stock is soaring higher on Wednesday after signing a deal with Regeneron Pharmaceuticals (REGN). 
Via InvestorPlace
News headline image
Decibel Therapeutics Stock Soars on Acquisition Deal - The Details ↗
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has agreed to acquire Decibel Therapeutics Inc (NASDAQ: DBTX) at $4.00 per share with an additional contingent value right of up to $3.50 per share in cash... 
Via Benzinga
News headline image
Earnings Scheduled For August 3, 2023 ↗
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million. 
Via Benzinga
News headline image
Regeneron Pharmaceuticals Earnings Preview ↗
 
Via Benzinga
News headline image
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $58,000 Today ↗
 
Via Benzinga
News headline image
P/E Ratio Insights for Regeneron Pharmaceuticals ↗
 
Via Benzinga
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Computer Task Group, Incorporated (Nasdaq - CTG), Decibel Therapeutics, Inc. (Nasdaq - DBTX)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Regeneron to Acquire Decibel Therapeutics, Strengthening Gene Therapy and Hearing Loss Programs
From Regeneron Pharmaceuticals, Inc.; Decibel Therapeutics, Inc.
Via GlobeNewswire
News headline image
3 AI Stocks You’ll Regret Not Buying Soon ↗
AI will have a big impact on biotech, which could help with drug discovery and create opportunities for these top AI stocks to invest in. 
Via InvestorPlace
News headline image
2 Top Stocks to Buy in August and Hold Forever ↗
These companies won't disappoint long-term investors. 
Via The Motley Fool
News headline image
Market Rally Under Pressure As Yields Soar; Amazon, ELF, Caterpillar Are Earnings Winners: Weekly Review ↗
Amazon, ELF and CAT were earnings winners, but there were big losers too. 
Via Investor's Business Daily
News headline image
Clorox, Boot Barn, Herbalife, Upwork And Other Big Stocks Moving Higher On Thursday ↗
U.S. stocks traded lower, with the Dow Jones falling around 100 points on Thursday. Here are some big stocks recording gains in today’s session. Traeger, Inc. (NYSE: COOK) shares jumped 43.2% to $5.90... 
Via Benzinga
News headline image
Why Is Regeneron Pharmaceuticals Moving Higher Today? ↗
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned second-quarter adjusted EPS of $10.24, up 5% Y/Y, beating the $9.92 Stre 
Via Benzinga
News headline image
US Stock Futures Dip As Apple, Amazon Earnings Loom: Analyst Warns Of 'Perfectly Normal' 5% Pullback This Month ↗
Stocks appear to be entrenched in an August swoon and it remains to be seen if big tech earnings provide a boost. 
Via Benzinga
News headline image
Regeneron Reports Second Quarter 2023 Financial and Operating Results
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Buy Alert: 3 Biotech Stocks Nearing Super Attractive Entry Points ↗
Investors looking to give their portfolio a boost should consider one of these leading biotech names, which are undervalued right now. 
Via InvestorPlace
News headline image
Regeneron Announces the 2023 Winners of The Regeneron Prize for Creative Innovation
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron Pharma Says Fewer Aflibercept Injections Maintains Vision, Anatomic Improvements In Diabetic Macular Edema ↗
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced the first presentation of two-year (96 weeks) results from the pivotal PHOTON trial of aflibercept 8 mg with 12- and 16-week dosing regimens,... 
Via Benzinga
News headline image
Aflibercept 8 mg Two-Year Results from Pivotal PHOTON Trial in Diabetic Macular Edema Presented at ASRS
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
57 58 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.